| 37.35 0.77 (2.1%) | 01-14 09:36 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 58.7  |
1-year : | 69.18 |
| Resists | First : | 50.26 |
Second : | 59.22 |
| Pivot price | 42.27 |
|||
| Supports | First : | 35.75 |
Second : | 29.74 |
| MAs | MA(5) : | 40 |
MA(20) : | 43.64 |
| MA(100) : | 51.55  |
MA(250) : | 29.53 |
|
| MACD | MACD : | -3.9 |
Signal : | -3.7 |
| %K %D | K(14,3) : | 7.7 |
D(3) : | 7.1 |
| RSI | RSI(14): 29.5 |
|||
| 52-week | High : | 66.91 | Low : | 6.44 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NKTR ] has closed below the lower bollinger band by 14.0%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 41.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 38.76 - 39.03 | 39.03 - 39.24 |
| Low: | 35.08 - 35.43 | 35.43 - 35.69 |
| Close: | 36.09 - 36.57 | 36.57 - 36.94 |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Tue, 13 Jan 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR - FinancialContent
Wed, 07 Jan 2026
How The Narrative Around Nektar Therapeutics (NKTR) Is Shifting With Rezpeg Data And Litigation Risks - Yahoo Finance
Mon, 05 Jan 2026
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead - The Motley Fool
Thu, 25 Dec 2025
More Unpleasant Surprises Could Be In Store For Nektar Therapeutics' (NASDAQ:NKTR) Shares After Tumbling 25% - simplywall.st
Sun, 21 Dec 2025
Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR) - Yahoo Finance
Thu, 18 Dec 2025
Assessing Nektar Therapeutics (NKTR) Valuation After a Volatile Year and Recent Share Price Pullback - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 20 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 71.1 (%) |
| Shares Short | 1,930 (K) |
| Shares Short P.Month | 1,810 (K) |
| EPS | -9.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.32 |
| Profit Margin | -192.9 % |
| Operating Margin | -267.5 % |
| Return on Assets (ttm) | -28 % |
| Return on Equity (ttm) | -180.3 % |
| Qtrly Rev. Growth | -51.1 % |
| Gross Profit (p.s.) | 2.68 |
| Sales Per Share | 3.07 |
| EBITDA (p.s.) | -6.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -190 (M) |
| Levered Free Cash Flow | -57 (M) |
| PE Ratio | -3.73 |
| PEG Ratio | 0 |
| Price to Book value | 8.44 |
| Price to Sales | 11.88 |
| Price to Cash Flow | -3.93 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|